Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Contingent Liabilities and Commitments (Details)

v3.25.1
Contingent Liabilities and Commitments (Details)
€ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Contingent Liabilities and Commitments [Line Items]        
Commission income expense € 25      
Annual royalties € 10      
Patent agreement, description (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority.      
Royalties in a total amount     € 850  
Royalty payments, percentage 10.00%      
Accrual | $   $ 0   $ 0
Minimum [Member]        
Contingent Liabilities and Commitments [Line Items]        
Percentage of net sales 2.00%      
Maximum [Member]        
Contingent Liabilities and Commitments [Line Items]        
Percentage of net sales (3.00%)